Genetic variation shapes how the immune system recognizes vaccines and, rarely, how it reacts adversely. Predictive factors fall into broad categories: genes encoding antigen-presentation machinery, innate immune sensors and signaling molecules, antibody and complement regulators, and genes that affect hemostasis. Understanding which variants matter supports targeted surveillance and safer vaccine design while remembering that serious reactions are uncommon and benefits of vaccination generally far outweigh risks.
HLA and adaptive-immune–mediated reactions
Variants in the human leukocyte antigen (HLA) region are the clearest predictive markers for immune-mediated adverse events. The strong association between HLA-DQB1*06:02 and the sharp rise in narcolepsy cases after the 2009 Pandemrix influenza campaign was documented by Finnish clinical investigators including Kari Partinen University of Helsinki and colleagues who reported the epidemiologic signal and prompted genetic follow-up. That HLA allele predisposes to autoimmune targeting of hypocretin-producing neurons; in this context vaccination acted as an environmental trigger in genetically susceptible individuals. More broadly, HLA alleles that favor presentation of particular peptide fragments can increase the chance of maladaptive T cell responses after exposure to a vaccine antigen.Innate sensors, coagulation, and allergic pathways
Polymorphisms in innate-immune genes such as Toll-like receptors (TLRs) and downstream signaling molecules can influence cytokine cascades and systemic reactogenicity. Variants in cytokine genes including IL1, IL6, and TNF have been associated with differing fever and inflammation responses to vaccines in multiple population studies, suggesting a genetic contribution to reactogenicity rather than frank autoimmunity. For rare thrombotic events associated with adenoviral-vector COVID-19 vaccines, mechanistic work led by Andreas Greinacher University Hospital Greifswald identified platelet factor 4 binding and anti-PF4 antibodies as central to vaccine-induced immune thrombotic thrombocytopenia; whether host genetic variants modulate that antibody response is an active research area. Severe immediate allergic reactions are often mediated by IgE to excipients such as polyethylene glycol; preexisting anti-PEG antibodies and genes controlling atopy could modulate risk.Relevance and consequences extend beyond biology: HLA allele frequencies vary by ancestry, so population-level risk differs geographically and culturally, affecting vaccine policy and communication. Clinically, genetic predictors currently inform investigation and research rather than routine pre-vaccination testing, because predictive value is limited and serious events remain rare. Ongoing large-scale genomics linked to vaccine safety surveillance aims to refine risk models that could one day enable personalized vaccination strategies without undermining public health benefits.